Economic Cost of Adverse Events Per Course of Therapy With Commonly Used First-Line Regimens for the Treatment of Chronic Lymphocytic Leukemia

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.463
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

Treatment Patterns, Adverse Events, and Economic Burden in a Privately Insured Population of Patients With Chronic Lymphocytic Leukemia in the United States

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Update on Therapy of Chronic Lymphocytic Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Management of Adverse Events Associated With Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues

Clinical Cancer Research
Cancer ResearchOncology
2008English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy
OncologyPharmacology
2015English

Consolidation Treatment With Lenalidomide Following Front-Line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Cost-Effectiveness of Adding Rituximab to Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia in Ukraine

Cancer Management and Research
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy